The European Medicines Agency will review drugs similar to Vioxx after Merck's withdrawal due to increased stroke and heart attack risks.
Pfizer's Celebrex is considered safer.
Merck faces lawsuits over Vioxx's health risks, impacting its revenue.
Vioxx's withdrawal led to a significant financial loss for Merck.
The company knew about Vioxx's dangers but continued marketing it.
Lawsuits against Merck are expected to increase due to Vioxx-related health issues.
Concerns about Vioxx's cardiovascular risks have been raised.
Vioxx lawsuits could surpass previous cases like Baycol and fen-phen.
